Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Relapse is the main cause of treatment failure for leukaemia patients with unfavourable gene mutations who receive allogeneic haematopoietic stem cell transplantation (allo‐HSCT). There is no consensus on the indication of donor lymphocyte infusion (DLI) for prophylaxis of relapse after allo‐HSCT. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Zhang, Rui, Wang, Lili, Chen, Peng, Gao, Xiaoning, Wang, Shuhong, Li, Fei, Dou, Liping, Gao, Chunji, Li, Yan, Liu, Daihong
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124122/
https://ncbi.nlm.nih.gov/pubmed/33932107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3763
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados